IGC Stock — IGC Pharma Inc.: Cash, EV, Pipeline

Share price

$0.28

Market cap

$29.5M

Cash

$0.4M

Enterprise value

$29.2M

Balance sheet

Cash	$0.4M
Debt	$0.1M
Net cash	$0.3M
Enterprise value	$29.2M
Basic shares	102.4M shares
Fully diluted shares	103.4M shares
Fully diluted market cap	$29.0M
Cash per share	$0.00

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading IGC daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Oct 24, 2026	IGC-AD1-Active	Phase 2	Alzheimer Disease; Agitation,Psychomotor; Care Giving Burden	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

IGC-AD1

Phase 2 · Active

Target CB1

Indications

agitation in Alzheimer's dementia (Phase 2)

Status note Lead candidate in CALMA, a randomized double-blind placebo-controlled Phase 2 trial; 146-patient enrollment target reached June 2026, over-enrollment and follow-up ongoing; database lock, site closeout and topline analysis expected next (no date stated). Phase 1 safety completed. Preclinical data suggest activity against AD pathology pathways.

TGR-63

Preclinical · Active

Target amyloid-beta (Aβ)

Indications

Alzheimer's disease (Preclinical)

Status note Earlier-stage candidate targeting AD mechanisms, in preclinical evaluation; no target, modality or indication detail stated.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	IGC-AD1-Active
Lead indication	Alzheimer Disease
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05543681	Phase 2	Recruiting	Sponsor	IGC Pharma, LLC	—	Alzheimer Disease; Agitation,Psychomotor; Care Giving Burden	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for IGC Pharma, LLC on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

IGC — IGC Pharma Inc.